Tarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals
August 6, 2026
Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront—$270 million in cash and $180 million in Tarsus stock—with up to $350 million in milestone payments and tiered royalties. Tarsus completed the acquisition on September 4, 2026, adding worldwide rights to Alkeus’s Phase 3 Stargardt disease therapy, gildeuretinol (ALK-001), to expand its retina pipeline and eye-care portfolio.
- Buyers
- Tarsus Pharmaceuticals, Inc.
- Targets
- Alkeus Pharmaceuticals, Inc.
- Sellers
- Alkeus stockholders
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioMarin Acquires Alesta Therapeutics
August 18, 2026
Biotechnology
BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.
-
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care
July 9, 2026
Biotechnology
Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.
-
Merck Acquires Terns Pharmaceuticals
March 26, 2026
Pharmaceuticals
Merck has agreed to acquire clinical-stage oncology company Terns Pharmaceuticals for approximately $6.7 billion (53.00 per share in cash). The deal is intended to add Terns’ lead asset TERN-701, an investigational oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia, to Merck’s hematology/oncology pipeline.
-
Novartis Acquires Regulus Therapeutics
June 25, 2025
Biotechnology
Novartis has completed the acquisition of Regulus Therapeutics, making Regulus an indirect wholly owned subsidiary following a tender offer and merger. The deal secures Regulus' investigational oligonucleotide therapy farabursen for ADPKD and strengthens Novartis' renal disease pipeline.
-
Alcon Acquires Majority Interest in Aurion Biotech, Inc.
March 26, 2025
Biotechnology
Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.
-
Alcon Acquires Aerie Pharmaceuticals, Inc.
August 22, 2022
Healthcare Services
Alcon entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, adding Rocklatan and Rhopressa commercial products along with AR-15512 and other ophthalmic pharmaceutical pipeline assets. The deal was funded with debt and was expected to close in Q4 2022, subject to customary approvals and conditions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.